This reflects a peculiar aspect of the interference with the TGF-β pathway in general—nearly the totality of the attempts made to target this pathway for cancer therapy have failed or showed only little improvement in survival, not justifying the adverse effects (especially cardiac) [98,99]. This evidence concerns the gene TGFB1 and cancer.